ArticleThe international journal of cardiovascular imaging2026
Cardiac Troponin release, myocardial function and inflammation in patients with takotsubo syndrome: a cardiac magnetic resonance study.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Takotsubo syndrome (TTS) is an acute heart failure phenotype characterized by transient left ventricular dysfunction and modest Troponin release. Mechanisms of myocardial injury remain unclear. We aimed to investigate relationships between Troponin T release, myocardial edema by cardiac magnetic resonance (CMR) T2 mapping, and systemic inflammatory biomarkers in TTS. Methods N = 94 patients with acute TTS underwent CMR (median 4 days after admission) and serial blood sampling during the index hospitalization. Patients were stratified by a previously defined prognostic relevant peak high-sensitivity Troponin T cut-off (≥ 28.8× upper limit of normal [ULN] vs. <28.8× ULN). Full blood count was obtained at admission and on the day of CMR. Results Mean age of the study population was 74 years, 7% male. Patients with higher Troponin release presented with more severe left ventricular systolic dysfunction (admission LVEF 36% vs. 41%, p = 0.005) and higher T2 mapping values (60 vs. 57 ms, p < 0.05). On the CMR day, higher NLR (3.7 ± 2.4 vs. 2.7 ± 1.4, p = 0.020) and lymphocyte-to-monocyte ratio (LMR) (3.2 ± 1.0 vs. 3.9 ± 1.6, p = 0.020) were observed in the high-Troponin release subgroup. Multivariable linear regression analysis identified admission LVEF (β=-0.524, p < 0.001), T2 mapping (β = 0.171, p = 0.045), NLR (β = 0.262, p = 0.032), and LMR (β=-0.282, p = 0.033) as independent correlates of Troponin release as a continuous variable. Conclusions Troponin release in TTS reflects an interplay between ventricular dysfunction, myocardial edema, and systemic inflammatory activation, supporting a non-ischemic pattern of myocardial injury. Troponin may serve as a simple surrogate marker of myocardial and systemic inflammation.
Indexed as
Identifiers
42370982What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.